APA (7th ed.) Citation

Hovanesian, J. A., Keyser, A., Berdy, G., & Sorensen, R. (2022). The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye. Clinical Ophthalmology, 16, 3841. https://doi.org/10.2147/OPTH.S387111

Chicago Style (17th ed.) Citation

Hovanesian, John A., Andrew Keyser, Gregg Berdy, and Robert Sorensen. "The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 Mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye." Clinical Ophthalmology 16 (2022): 3841. https://doi.org/10.2147/OPTH.S387111.

MLA (9th ed.) Citation

Hovanesian, John A., et al. "The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 Mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye." Clinical Ophthalmology, vol. 16, 2022, p. 3841, https://doi.org/10.2147/OPTH.S387111.